The World Bank Working for a World Free of Poverty Microdata Library
  • Data Catalog
  • About
  • Collections
  • Citations
  • Terms of use
  • Login
    Login
    Home / Central Data Catalog / IMPACT_EVALUATION / BFA_2017_HRBFIE-FEL_V01_M / variable [F8]
impact_evaluation

Results-Based Financing Impact Evaluation Health Facility 2017, Endline Survey

Burkina Faso, 2017
Get Microdata
Reference ID
BFA_2017_HRBFIE-FEL_v01_M
DOI
https://doi.org/10.48529/01gp-gm52
Producer(s)
Manuela de Allegri, Herve Hien, Paul Jacob Robyn
Collection(s)
Impact Evaluation Surveys Fragility, Conflict and Violence
Metadata
Documentation in PDF DDI/XML JSON
Created on
Aug 27, 2019
Last modified
Oct 01, 2019
Page views
204695
Downloads
2614
  • Study Description
  • Data Description
  • Documentation
  • Get Microdata
  • Related datasets
  • Data files
  • f1_jul19
  • f1p_jul19
  • f1u_jul19
  • f2_jul19
  • f3_jul19
  • f4_jul19
  • f5_jul19
  • f6_jul19
  • f7_jul19

F6_220_M (f6_220_4)

Data file: f6_jul19

Overview

Valid: 213
Invalid: 0
Type: Discrete
Start: 645
End: 672
Width: 28
Range: -
Format: character

Questions and instructions

Categories
Value Category Cases
0 1
0.5%
00 12
5.6%
2 2
0.9%
AGA Q 1
0.5%
AL b6 1
0.5%
ASL 1
0.5%
Albendazol 1
0.5%
Albendazole 1
0.5%
Amoxiciline 1
0.5%
Amoxicilline 3
1.4%
Artemether+lumefantrine 1
0.5%
Atemether +Lumefan 20/120 1
0.5%
CHLORPHENIRAMINE 1
0.5%
CLORPHENAMINE 1
0.5%
COARTEM 2
0.9%
COTRIMOXAZOL 1
0.5%
Chlor 3
1.4%
Chloropheramine 1
0.5%
Chlorpheniramine 1
0.5%
Cotri 1
0.5%
Cotrimoxazole 1
0.5%
Cs 1
0.5%
Fer sirop 1
0.5%
Fer solution 1
0.5%
G-Ceftria 1
0.5%
Gant 1
0.5%
Gant d'examen 1
0.5%
Lumartem 1
0.5%
METRONIDAZOLE 1
0.5%
Mebendazole 4
1.9%
Metoclopramide cp 1
0.5%
Metri 1
0.5%
Metronidazole 1
0.5%
PARA 1
0.5%
PARACETAMOL 5
2.3%
POLYVIDONE IODEE 1
0.5%
Para 1
0.5%
Para cp 1
0.5%
Paracetamol 1
0.5%
Paracetamol comp 1
0.5%
Paracetamol inj 1
0.5%
Penta 2 1
0.5%
Rota 1 1
0.5%
SRO ZINC 12
5.6%
SRO Zinc 2
0.9%
SRO zinc 2
0.9%
SRO-ZINC 2
0.9%
Seringue 10cc 1
0.5%
Seringue-Guant 1
0.5%
Sro Zinc 1
0.5%
Zinc 1
0.5%
acide salicylique 1
0.5%
albendazole 1
0.5%
albendazole siro 2
0.9%
amoxi,para 1
0.5%
amoxicillin buv. 1
0.5%
amoxicilline 3
1.4%
amoxicilline srp 1
0.5%
artemether 3
1.4%
artemether/lumefantrine 1
0.5%
artezunate 1
0.5%
attemether lumefantrine 1
0.5%
bactigen collyre 1
0.5%
betadine 1
0.5%
carbocisteine 1
0.5%
carbocyst 1
0.5%
carbocysteine 2
0.9%
carbocysteine sirop 1
0.5%
carbotoux 2
0.9%
carbotoux 2% 2
0.9%
chlirphenamine 1
0.5%
chlorepheniramine 1
0.5%
chlorepheramine 1
0.5%
chlorephetamine 1
0.5%
chlorphenamine 1
0.5%
chlorphenamine 4mg 1
0.5%
chlorpheneramine 1
0.5%
chlorpheniramine 3
1.4%
chlorphenoramine cp 1
0.5%
chlorpheramin 1
0.5%
chlorpheramine 1
0.5%
coartem 3
1.4%
cotri 4
1.9%
cotri cp 1
0.5%
cotri sp 1
0.5%
cotrimoxazole 2
0.9%
cotrimoxazole sirop 1
0.5%
erytromicine sirop 1
0.5%
fer-acide follique 1
0.5%
gant 4
1.9%
gant sparadra compress 1
0.5%
gentamicine 1
0.5%
gentamycine collyre 1
0.5%
mebendazol 1
0.5%
mebendazole 8
3.8%
mebendazole cp 1
0.5%
mebendazole cp 100mg 1
0.5%
meto inj 1
0.5%
metronidazol 2
0.9%
metronidazole 2
0.9%
metronidazole 125mg 1
0.5%
multivitamine 1
0.5%
mébendazole 1
0.5%
nystatine pommade 1
0.5%
para 4
1.9%
para cp 3
1.4%
para sirop 1
0.5%
para,chlor 1
0.5%
paracetamol 2
0.9%
paracetamol 100mg 1
0.5%
paracetamol 500mg 2
0.9%
paracetamol comp 1
0.5%
paracetamol cp 1
0.5%
paracétamol 500mg 1
0.5%
perfalgan inj 1
0.5%
phenoxymethylpenicillie 1
0.5%
primalan 1
0.5%
seringue 2
0.9%
sjlfamethoxazole 1
0.5%
solution de glucose 1
0.5%
solution orale para 1
0.5%
sparadrap 1
0.5%
sro zinc 5
2.3%
sro+zinc 1
0.5%
srozinc 2
0.9%
sulfadoxine+pyrimethamine cp 1
0.5%
sulfamethoxazol 1
0.5%
sulfamethoxazole 3
1.4%
sulfametoxazole 1
0.5%
sulfate de zinc 1
0.5%
sulfate de zinc comp 1
0.5%
tetracycline 1
0.5%
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.
Back to Catalog
The World Bank Working for a World Free of Poverty
  • IBRD IDA IFC MIGA ICSID

© The World Bank Group, All Rights Reserved.

This site uses cookies to optimize functionality and give you the best possible experience. If you continue to navigate this website beyond this page, cookies will be placed on your browser. To learn more about cookies, click here.